FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

研究/Real-World Study Launches to Track Weight Loss and Well-being After Semaglutide Treatment for Severe Obesity
研究ライブラリに戻る

Real-World Study Launches to Track Weight Loss and Well-being After Semaglutide Treatment for Severe Obesity

November 20, 2026
Share
発展中の研究

これらは有望ですが、さらなる検証が必要な発展途上の見解に基づいています。

この分析について

この記事は、最近のニュースアイテムや臨床試験リストのAI補助要約です。ペプチド研究コミュニティにとって迅速でアクセスしやすい概要を提供することを目的としています。正確性のために常に下記リンク先の元のソースをご確認ください。

Real-World Study Launches to Track Weight Loss and Well-being After Semaglutide Treatment for Severe Obesity

A new real-world follow-up study has been launched in France to evaluate the long-term impact of semaglutide treatment on individuals with severe obesity. The SEMAFOLLOW study, registered under ClinicalTrials.gov as NCT07423481, aims to gather detailed information about weight trajectories and predictive factors for patients who have undergone treatment with WEGOVY® (semaglutide 2.4 mg). This research is crucial for understanding the effectiveness of peptide therapy in managing severe obesity.

Background

Obesity is a complex condition that affects millions of people worldwide, leading to numerous health complications such as cardiovascular disease and diabetes. In recent years, semaglutide has emerged as an effective treatment option for individuals struggling with weight management. Semaglutide works by mimicking the action of GLP-1 (glucagon-like peptide 1), a hormone that helps regulate blood sugar levels and promotes feelings of fullness.

In France, WEGOVY® is available under temporary authorisation for use (ATU) and an early access programme. This means that patients who meet specific criteria can receive the treatment before it has been fully approved by regulatory bodies like the FDA. The SEMAFOLLOW study seeks to gather data from these real-world settings to provide valuable insights into how semaglutide performs in a broader population.

Key Details

The SEMAFOLLOW study is being conducted by teams of specialists from various obesity centres across France, ensuring a comprehensive evaluation of treatment outcomes. Participants will be followed up over an extended period to track their weight changes, assess the effectiveness of different treatment strategies, and evaluate overall well-being. The study uses the SEMAFOLLOW questionnaire to gather detailed information about patients' experiences with semaglutide.

This research is particularly important because it focuses on individuals with grade 3 obesity (BMI ≥40 kg/m²) or those with obesity-related complications. These patients often face significant challenges in managing their weight and improving their health outcomes, making the findings from this study highly relevant for both clinicians and researchers working in the field of peptide therapy.

Key Takeaways

  • Comprehensive Evaluation: The SEMAFOLLOW study provides a detailed look at how semaglutide performs over time in real-world settings.
  • Patient-Centered Approach: By using the SEMAFOLLOW questionnaire, the study captures the patient's perspective on treatment effectiveness and well-being.
  • Focus on Severe Cases: This research targets individuals with grade 3 obesity or those with severe complications, offering insights that are directly applicable to high-risk patients.
  • Collaborative Effort: The involvement of multiple specialist teams ensures a thorough assessment of semaglutide's impact across different patient populations.

What This Means

For the peptide community, the SEMAFOLLOW study represents an important step forward in understanding the long-term benefits and challenges associated with semaglutide treatment. As more data becomes available from real-world applications, clinicians can make better-informed decisions about which patients might benefit most from this therapy. Additionally, researchers will have valuable information to guide future studies on peptide therapies for obesity management.

The findings from SEMAFOLLOW could also influence regulatory discussions around the approval and use of semaglutide in other regions, including potential FDA regulation updates. This study underscores the importance of ongoing research into peptide-based treatments as a cornerstone of modern weight management strategies.

---

Source: ClinicalTrials.gov — Published 2026-11-19

This article is for informational purposes only and does not constitute medical advice.

編集者の注

この分析はAIツールを使用して生成され、Peptide Contacts編集部がレビューしました。正確性を追求していますが、AI生成のコンテンツには誤りや省略がある可能性があります。情報確認のために常に元のソースをご確認ください。 元のソース 詳細、方法論、データについては

Peptide Contactsは、情報提供のために-curated研究要約を提供しています。このコンテンツは医療アドバイスにはなりません。健康決定をする前に常に格付けされた医療専門家に相談してください。

Comments

Sign in to join the discussion

この記事はAIを使用して生成され、誤りや省略がある可能性があります。情報提供のために提供されていますが、医療アドバイスにはなりません。常に元のソースを確認し、格付けされた医療専門家に相談してください。